Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.74 CHF | -0.36% | -2.92% | +3.38% |
Dec. 12 | Unsupported price hikes added $815 million to US drug spending in 2023 | RE |
Dec. 11 | Monte Rosa Closes Global License Agreement With Novartis | MT |
Composite Fundamentals | Composite Valuation | Composite Consensus | Composite Momentum | Composite Visibility | Investor Rating | ESG Refinitiv | Capi. ($) | ||
---|---|---|---|---|---|---|---|---|---|
B- | 198B | ||||||||
C+ | 704B | ||||||||
B | 488B | ||||||||
C+ | 352B | ||||||||
C+ | 306B | ||||||||
B- | 256B | ||||||||
A+ | 231B | ||||||||
B+ | 208B | ||||||||
C+ | 147B | ||||||||
C+ | 144B | ||||||||
B+ | 119B | ||||||||
B- | 115B | ||||||||
B | 114B | ||||||||
A- | 73.18B | ||||||||
B | 69.14B | ||||||||
A- | 55.05B | ||||||||
B | 43.77B | ||||||||
B+ | 43.19B | ||||||||
B | 42.03B | ||||||||
Average | B | 195.28B | |||||||
Weighted average by Cap. | B |
- Stock Market
- Equities
- NOVN Stock
- Sector Novartis AG
- Sector ratings